Racial Disparities in the Rate of Cardiotoxicity of HER2-Targeted Therapies Among Women With Early Breast Cancer
Racial Disparities in the Rate of Cardiotoxicity of HER2-Targeted Therapies Among Women With Early Breast Cancer
复制标题
DOI：
10.1002/cncr.31260
复制
发表时间：
2018-05-01
期刊：
影响因子：
6.2
通讯作者：
Connolly, Roisin M.
中科院分区：
文献类型：
--
作者：
Litvak, Anya;Batukbhai, Bhavina;Connolly, Roisin M.
背景技术背景：人表皮生长因子受体2（HER2）靶向治疗在预防乳腺癌复发方面非常有效，但在某些患者中与心脏毒性相关，并且关于这种毒性发生率的种族差异的数据很少。作者进行了一项回顾性研究，分析了黑人或白色人种与HER2阳性早期乳腺癌患者中治疗诱导的心脏毒性和治疗不完全的相关性。方法：2005年1月至2015年3月期间在作者所在机构开始（新）辅助HER 2靶向治疗（曲妥珠单抗联合或不联合帕妥珠单抗）的HER 2阳性I至III期乳腺癌女性有资格。我们分析了心脏毒性（左心室射血分数较基线下降≥ 10%）和治疗不完全（
BACKGROUND: Human epidermal growth factor receptor 2 (HER2)-targeted therapies are highly effective at preventing breast cancer recurrence but are associated with cardiotoxicity in some patients, and minimal data are available regarding racial disparities in the incidence of this toxicity. The authors conducted a retrospective study to analyze the association of black or white race with treatment-induced cardiotoxicity and incomplete therapy among patients with HER2-positive early breast cancer. METHODS: Women with HER2-positive, stage I through III breast cancer who initiated (neo) adjuvant HER2-targeted therapy (trastuzumab with or without pertuzumab) from January 2005 to March 2015 at the authors' institution were eligible. We analyzed differences in the incidence of cardiotoxicity (a decline in the left ventricular ejection fraction to = 10% from baseline) and incomplete therapy (